-
-
-
-
-
-
-
Sanofi (SNY) Says Phase 3 LixiLan-O, LixiLan-L Trials Met Primary Endpoints
-
-
-
-
-
-
-
Sanofi Reports Positive Top-Line Results in Second Pivotal LixiLan Phase III Study
-
-
-
-
-
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

